As of January 31, 2025, Aion Therapeutic Inc. has 497.15M shares outstanding.
| Shares Outstanding | 497.15M |
These figures are as of January 31, 2025. The price-to-sales ratio is 3.24, and the price-to-book ratio stands at -0.68.
| PS Ratio | 3.24 |
| PB Ratio | -0.68 |
| P/TBV Ratio | -1.02 |
| P/FCF Ratio | -3.09 |
| P/OCF Ratio | -3.09 |
These figures are as of January 31, 2025. The EV/Sales ratio of 5.14 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.
| EV / Sales | 5.14 |
As of January 31, 2025, Aion Therapeutic Inc. maintains a current ratio of 0.19, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -60.12, indicating conservative leverage, while an interest coverage ratio of -4.41 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.19 |
| Quick Ratio | 0.03 |
| Debt / Equity | -60.12 |
| Debt / EBITDA | -1.92 |
| Interest Coverage | -4.41 |
These figures cover the twelve months ended January 31, 2025. Return on assets (ROA) is negative at -187.35, reflecting losses generated across the asset base. Inventory turnover of 2.28 indicates how many times Aion Therapeutic Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Assets (ROA) | -187.35 |
| Inventory Turnover | 2.28 |
As of the close on October 1, 2025, Aion Therapeutic Inc.'s stock has declined approximately 66.67% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.01.
| 52-Week Price Change | -66.67% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.01 |
Over the twelve months ended January 31, 2025, Aion Therapeutic Inc. posted a gross margin of 37.50, reflecting its pricing power and cost economics. The operating margin of -107.43 and net profit margin of -451.18 provide insight into operational efficiency.
| Gross Margin | 37.50 |
| Operating Margin | -107.43 |
| Pretax Margin | -451.18 |
| Profit Margin | -451.18 |
| EBITDA Margin | -99.13 |
These figures cover the twelve months ended January 31, 2025. Free cash flow yield is negative at -32.35: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -29.55, meaning Aion Therapeutic Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -29.55 |
| FCF Yield | -32.35 |
As of January 31, 2025, Aion Therapeutic Inc. has an Altman Z-Score of -39.40, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -39.40 |
Already premium?